Phaseline

Companies › Wooshin Labottach

Wooshin Labottach: clinical trials, targets and expected readouts

1 active drug program in 1 registered trial: 1 Phase 3; Immunology; next expected readout Nov 2026.

Open in Phaseline: competitors, likelihood bands and readouts Company report

Programs

DrugTargetHighest phaseConditionsNext expected readout
Cosmetic patch containing urea
Topical urea application
–Phase 3Nail PsoriasisNov 2026

Trials

Registry idDrugPhaseConditionsAreaExpected readout
NCT07029516Cosmetic patch containing ureaPhase 3Nail PsoriasisImmunologyNov 2026

Targets

No annotated target.

Companies with the same targets

–

Companies built like this

R-Bio Lipogems International PainTEQ CellSeed Cellcolabs Clinical SPV

Pipelines of the same shape: areas, drug types, target families, stage and cash runway.

Programs group the company's trials by drug; the target and mechanism come from Open Targets and ChEMBL via Open Targets; expected readouts are Phaseline's estimate from the registry's primary completion date. Facts from the registries only; the approval likelihood, shown as a band with its track record, is in the app.